Pharmacist-Driven Transitions of Care Practice Model for Prescribing Oral Antimicrobials at Hospital Discharge.
Journal
JAMA network open
ISSN: 2574-3805
Titre abrégé: JAMA Netw Open
Pays: United States
ID NLM: 101729235
Informations de publication
Date de publication:
02 05 2022
02 05 2022
Historique:
entrez:
10
5
2022
pubmed:
11
5
2022
medline:
14
5
2022
Statut:
epublish
Résumé
Although prescribers face numerous patient-centered challenges during transitions of care (TOC) at hospital discharge, prolonged duration of antimicrobial therapy for common infections remains problematic, and resources are needed for antimicrobial stewardship throughout this period. To evaluate a pharmacist-driven intervention designed to improve selection and duration of oral antimicrobial therapy prescribed at hospital discharge for common infections. This quality improvement study used a nonrandomized stepped-wedge design with 3 study phases from September 1, 2018, to August 31, 2019. Seventeen distinct medicine, surgery, and specialty units from a health system in Southeast Michigan participated, including 1 academic tertiary hospital and 4 community hospitals. Hospitalized adults who had urinary, respiratory, skin and/or soft tissue, and intra-abdominal infections and were prescribed antimicrobials at discharge were included in the analysis. Data were analyzed from February 18, 2020, to February 28, 2022. Clinical pharmacists engaged in a new standard of care for antimicrobial stewardship practices during TOC by identifying patients to be discharged with a prescription for oral antimicrobials and collaborating with primary teams to prescribe optimal therapy. Academic and community hospitals used both antimicrobial stewardship and clinical pharmacists in a multidisciplinary rounding model to discuss, document, and facilitate order entry of the antimicrobial prescription at discharge. The primary end point was frequency of optimized antimicrobial prescription at discharge. Health system guidelines developed from national guidelines and best practices for short-course therapies were used to evaluate optimal therapy. A total of 800 patients prescribed oral antimicrobials at hospital discharge were included in the analysis (441 women [55.1%]; mean [SD] age, 66.8 [17.3] years): 400 in the preintervention period and 400 in the postintervention period. The most common diagnoses were pneumonia (264 [33.0%]), upper respiratory tract infection and/or acute exacerbation of chronic obstructive pulmonary disease (214 [26.8%]), and urinary tract infection (203 [25.4%]). Patients in the postintervention group were more likely to have an optimal antimicrobial prescription (time-adjusted generalized estimating equation odds ratio, 5.63 [95% CI, 3.69-8.60]). The absolute increase in optimal prescribing in the postintervention group was consistent in both academic (37.4% [95% CI, 27.5%-46.7%]) and community (43.2% [95% CI, 32.4%-52.8%]) TOC models. There were no differences in clinical resolution or mortality. Fewer severe antimicrobial-related adverse effects (time-adjusted generalized estimating equation odds ratio, 0.40 [95% CI, 0.18-0.88]) were identified in the postintervention (13 [3.2%]) compared with the preintervention (36 [9.0%]) groups. The findings of this quality improvement study suggest that targeted antimicrobial stewardship interventions during TOC were associated with increased optimal, guideline-concordant antimicrobial prescriptions at discharge.
Identifiants
pubmed: 35536577
pii: 2792123
doi: 10.1001/jamanetworkopen.2022.11331
pmc: PMC9092199
doi:
Substances chimiques
Anti-Bacterial Agents
0
Anti-Infective Agents
0
Types de publication
Journal Article
Research Support, U.S. Gov't, P.H.S.
Langues
eng
Sous-ensembles de citation
IM
Pagination
e2211331Références
PLoS One. 2016 Jun 16;11(6):e0157671
pubmed: 27309536
BMC Infect Dis. 2018 May 16;18(1):225
pubmed: 29769028
Am J Health Syst Pharm. 2022 Mar 7;79(6):477-485
pubmed: 34636856
Infect Control Hosp Epidemiol. 2020 Oct;41(10):1225-1227
pubmed: 32484116
Clin Microbiol Infect. 2020 Mar;26(3):327-332
pubmed: 31600582
Clin Infect Dis. 2018 Sep 28;67(8):1306-1307
pubmed: 29659764
Clin Infect Dis. 2019 Sep 27;69(8):1269-1277
pubmed: 30759198
Am J Health Syst Pharm. 2019 Jun 3;76(12):861-868
pubmed: 31361849
Infect Control Hosp Epidemiol. 2017 May;38(5):534-541
pubmed: 28260538
Open Forum Infect Dis. 2020 Apr 30;7(5):ofaa149
pubmed: 32500088
Infect Dis Ther. 2018 Dec;7(4):439-455
pubmed: 30270406
MMWR Recomm Rep. 2016 Nov 11;65(6):1-12
pubmed: 27832047
JAMA Netw Open. 2021 Mar 1;4(3):e212007
pubmed: 33734417
Ann Intern Med. 2019 Aug 6;171(3):153-163
pubmed: 31284301
Clin Infect Dis. 2021 Dec 6;73(11):e4499-e4506
pubmed: 32918077
Clin Infect Dis. 2016 Dec 15;63(12):1639-1644
pubmed: 27682070
Clin Infect Dis. 2016 May 15;62(10):e51-77
pubmed: 27080992
Clin Infect Dis. 2018 Apr 17;66(9):1333-1341
pubmed: 29126268
Jt Comm J Qual Patient Saf. 2022 Jan;48(1):40-52
pubmed: 34764025
Infect Control Hosp Epidemiol. 2017 Mar;38(3):353-355
pubmed: 27890038
JAMA Intern Med. 2017 Sep 1;177(9):1308-1315
pubmed: 28604925
JAMA Intern Med. 2016 Sep 1;176(9):1254-5
pubmed: 27455385
Hosp Pharm. 2021 Dec;56(6):714-717
pubmed: 34732928